The effect of the intestinal microbiota on the development of diabetes mellitus
https://doi.org/10.31146/1682-8658-ecg-220-12-77-85
Abstract
The aim of the study was to identify the pathogenetic role of intestinal microflora in the development of diabetes mellitus. The review presents data on the peculiarities of the development of the intestinal microflora (MC), factors that determine the occurrence of dysbiosis, as well as the effect of dysbiotic changes in MC on the pathogenesis of various types of diabetes mellitus. The role of MC in the occurrence of insulin resistance, as well as the metabolism of peptides that determine eating behavior, has been studied. The contribution of short-chain fatty acids produced by microorganisms to the regulation of metabolism in diabetes mellitus is considered, and the role of pathogenicity factors of MC representatives is studied. Conclusion. The gut microbiota makes a significant contribution to the regulation of metabolism through various mechanisms. The resulting dysbiotic changes can negatively affect metabolic processes and be a risk factor for the development of diabetes mellitus. The identification of new pathogenetic pathways can be useful in finding points of application of drug therapy, which will contribute to improving the results of DM treatment.
About the Authors
V. M. Chervinets
Tver State Medical University
Russian Federation
Russian Federation
Yu. V. Chervinets
Tver State Medical University
Russian Federation
Russian Federation
D. V. Ganzya
Tver State Medical University
Russian Federation
Russian Federation
V. S. Belyaev
Tver State Medical University
Russian Federation
Russian Federation
V. S. Zaitseva
Tver State Medical University
Russian Federation
Russian Federation
References
1. Liu Y., Lou X. Type 2 diabetes mellitus-related environmental factors and the gut microbiota: emerging evidence and challenges. Clinics (Sao Paulo). 2020 Jan 10;75: e1277. doi: 10.6061/clinics/2020/e1277.
2. Cani P.D., Amar J., Iglesias M. A. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007 Jul;56(7):1761-72. doi: 10.2337/db06-1491.
3. Tilg H., Moschen A. R. Microbiota and diabetes: an evolving relationship. Gut. 2014 Sep;63(9):1513-21. doi: 10.1136/gutjnl-2014-306928.
4. Mashkova M.A., Mokhort T. V. Role of gut microbiota in obesity and type 2 diabetes mellitus. Lech delo. 2016;51(5):64-70. (in Russ.)@@ Машкова М. А., Мохорт Т. В. Роль кишечной микрофлоры в развитии ожирения и сахарного диабета 2 типа. Лечебное дело: научно-практический терапевтический журнал. 2016;51(5):64-70.
5. Luca M., Di Mauro M., Di Mauro M., Luca A. Gut Microbiota in Alzheimer’s Disease, Depression, and Type 2 Diabetes Mellitus: The Role of Oxidative Stress. Oxid Med Cell Longev. 2019 Apr 17;2019:4730539. doi: 10.1155/2019/4730539.
6. Chernin V.V., Parfenov A. I., Bondarenko V. M., Rybalchenko O. V., Chervinets V. M. [Symbiont digestion in humans. Physiology. Clinic, diagnosis and treatment of its disorders]. Moscow. “Triad” Publ., 2013. 232 P. (in Russ.)@@ Чернин В. В., Парфенов А. И., Бондаренко В. М., Рыбальченко О. В., Червинец В. М. Симбионтное пищеварение человека. Физиология. Клиника, диагностика и лечение его нарушений. Монография. 2013 г. Изд. «Триада», 232 стр.
7. Drucker D. J. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 Apr 3;27(4):740-756. doi: 10.1016/j.cmet.2018.03.001.
8. Pokrovskaya E.V., Shamkhalova M. S., Shestakova M. V. The new views on the state of the gut microbiota in obesity and diabetes mellitus type 2. Diabetes mellitus. 2019;22(3):253-262. (In Russ.) doi: 10.14341/DM10194.@@ Покровская Е. В., Шамхалова М. Ш., Шестакова М. В. Новые взгляды на состояние кишечной микробиоты при ожирении и сахарном диабете 2 типа. Сахарный диабет. 2019;22(3):253-262. doi: 10.14341/DM10194.
9. Scheithauer T.P.M., Rampanelli E., Nieuwdorp M., Vallance B. A., Verchere C. B., van Raalte D. H., Herrema H. Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes. Front Immunol. 2020 Oct 16;11:571731. doi: 10.3389/fimmu.2020.571731.
10. Woldeamlak B., Yirdaw K., Biadgo B. Role of Gut Microbiota in Type 2 Diabetes Mellitus and Its Complications: Novel Insights and Potential Intervention Strategies. Korean J Gastroenterol. 2019 Dec 25;74(6):314-320. doi: 10.4166/kjg.2019.74.6.314.
11. Aw W., Fukuda S. Understanding the role of the gut ecosystem in diabetes mellitus. J Diabetes Investig. 2018 Jan;9(1):5-12. doi: 10.1111/jdi.12673.
12. Mikhelson E. Yu., Lepshokova Z. M., Khadzhilaeva F. D. The role of gastrointestinal microbiota in the development of gestational diabetes mellitus. My professional career. 2020;1(10):155-158. (in Russ.)@@ Михельсон Э. Ю., Лепшокова З. М., Хаджилаева Ф. Д. Роль микробиоты желудочно-кишечного тракта в развитии гестационного сахарного диабета. Моя профессиональная карьера. 2020. Т. 1. № 10. С. 155-158.
13. Scheithauer T.P.M., Rampanelli E., Nieuwdorp M. et al. Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes. Front Immunol. 2020;11:571731. doi:10.3389/fimmu.2020.571731.
14. Lupien-Meilleur J., Andrich D. E., Quinn S., Micaelli-Baret C., St-Amand R., Roy D., St-Pierre D. H.Interplay Between Gut Microbiota and Gastrointestinal Peptides: Potential Outcomes on the Regulation of Glucose Control. Can J Diabetes. 2020 Jun;44(4):359-367. doi: 10.1016/j.jcjd.2019.10.006.
15. Meier J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012 Dec;8(12):728-42. doi: 10.1038/nrendo.2012.140.
16. van der Klauw M. M., Wolffenbuttel B. H. The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes.Neth J Med. 2012 Dec;70(10):436-43. PMID: 23230012.
17. Drucker D. J. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 Apr 3;27(4):740-756. doi: 10.1016/j.cmet.2018.03.001.
18. Maselli D.B., Camilleri M. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. Adv Exp Med Biol. 2021;1307:171-192. doi: 10.1007/5584_2020_496.
19. Urakov A.L., Gurevich K. G., Sorokina I. A., Lovtsova L. V., Zanozina O. V., Barsuk A. L. Relationship of clinical efficacy of glucose lowering agents, gut microbiota, diet, and patient’s genotype in diabetes mellitus type 2. Reviews on Clinical Pharmacology and Drug Therapy. 2018;16(4):11-18. (in Russ.) doi: 10.17816/RCF16411-18.@@ Ураков А. Л., Гуревич К. Г., Сорокина Ю. А., Ловцова Л. В., Занозина О. В., Барсук А. Л. Взаимосвязь клинической эффективности сахароснижающих препаратов, микробиоты кишечника, рациона питания и генотипа пациента при сахарном диабете 2-го типа. Обзоры по клинической фармакологии и лекарственной терапии. 2018. Т. 16. № 4. С. 11-18. doi: 10.17816/RCF16411-18.
20. McCreight L.J., Bailey C. J., Pearson E. R. Metformin and the gastrointestinal tract. Diabetologia. 2016 Mar;59(3):426-35. doi: 10.1007/s00125-015-3844-9.
21. Khachaturyan N.E., Egshatyan L. V.Intestinal Microbiota Modulation by Metformin. Effective pharmacotherapy. 2017. No. 43. pp. 20-29. (in Russ.)@@ Хачатурян Н. Э., Егшатян Л. В. Модуляция кишечной микробиоты метформином. Эффективная фармакотерапия. 2017. № 43. С. 20-29.
22. Ametov A.S., Karpova E. V. Clinical use of the DPP-4 inhibitor vildagliptin in type 2 diabetes mellitus. Polyclinic. 2010;(5):24-28. (in Russ.)@@ Аметов А. С., Карпова Е. В. Клиническое использование ингибитора дпп-4 - вилдаглиптина при сахарном диабете 2 типа. Поликлиника. 2010. № 5. С. 24-28.
23. Tang R., Li L. Modulation of Short-Chain Fatty Acids as Potential Therapy Method for Type 2 Diabetes Mellitus. Can J Infect Dis Med Microbiol. 2021;2021:6632266. doi:10.1155/2021/6632266.
24. Huang W., Man Y., Gao C. et al. Short-Chain Fatty Acids Ameliorate Diabetic Nephropathy via GPR43-Mediated Inhibition of Oxidative Stress and NF-κB Signaling. Oxid Med Cell Longev. 2020;2020:4074832. doi: 10.1155/2020/4074832.
25. Yang Q., Ouyang J., Sun F., Yang J. Short-Chain Fatty Acids: A Soldier Fighting Against Inflammation and Protecting From Tumorigenesis in People With Diabetes. Front Immunol. 2020;11:590685. doi: 10.3389/fimmu.2020.590685.
26. Tran S.M., Mohajeri M. H. The Role of Gut Bacterial Metabolites in Brain Development, Aging and Disease. Nutrients. 2021;13(3):732. doi:10.3390/nu13030732.
27. Tanase D.M., Gosav E. M., Neculae E. et al. Role of Gut Microbiota on Onset and Progression of Microvascular Complications of Type 2 Diabetes (T2DM). Nutrients. 2020;12(12):3719. doi:10.3390/nu12123719.
28. Markowiak-Kopeć P., Śliżewska K. The Effect of Probiotics on the Production of Short-Chain Fatty Acids by Human Intestinal Microbiome. Nutrients. 2020;12(4):1107. doi:10.3390/nu12041107.
29. Boulangé C.L., Neves A. L., Chilloux J., Nicholson J. K., Dumas M. E. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016;8(1):42. doi:10.1186/s13073-016-0303-2.
30. McNabney S.M., Henagan T. M. Short Chain Fatty Acids in the Colon and Peripheral Tissues: A Focus on Butyrate, Colon Cancer, Obesity and Insulin Resistance. Nutrients. 2017;9(12):1348. doi:10.3390/nu9121348/
31. Li W.Z., Stirling K., Yang J. J., Zhang L. Gut microbiota and diabetes: From correlation to causality and mechanism. World J Diabetes. 2020;11(7):293-308. doi:10.4239/wjd.v11.i7.293.
32. Ermak I.M., Davydova V. N. [Interaction of bacterial lipopolysaccharides with soluble proteins of the macroorganism and polycations]. Biological membranes. 2008;25(5):323-342. (in Russ.)@@ Ермак И. М., Давыдова В. Н. Взаимодействие бактериальных липополисахаридов с растворимыми белками макроорганизма и поликатионам. Биологические мембраны. 2008. Т. 25. № 5. С. 323-342.
33. Salazar J., Angarita L., Morillo V. et al. Microbiota and Diabetes Mellitus: Role of Lipid Mediators. Nutrients. 2020;12(10):3039. doi:10.3390/nu12103039.
34. Krumbeck J.A., Rasmussen H. E., Hutkins R. W. et al. Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome. 2018;6(1):121. doi:10.1186/s40168-018-0494-4.
35. Plaza-Díaz J., Solís-Urra P., Rodríguez-Rodríguez F. et al. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage.Int J Mol Sci. 2020;21(21):8351. doi:10.3390/ijms21218351.
36. Sorini C., Cosorich I., Lo Conte M. et al. Loss of gut barrier integrity triggers activation of islet-reactive T cells and autoimmune diabetes. Proc Natl Acad Sci U S A. 2019;116(30):15140-15149. doi:10.1073/pnas.1814558116.
37. Li B.Y., Xu X. Y., Gan R. Y. et al. Targeting Gut Microbiota for the Prevention and Management of Diabetes Mellitus by Dietary Natural Products. Foods. 2019;8(10):440. doi:10.3390/foods8100440.
38. Muñoz-Garach A., Diaz-Perdigones C., Tinahones F. J. Gut microbiota and type 2 diabetes mellitus. Endocrinol Nutr. 2016 Dec;63(10):560-568. English, Spanish. doi: 10.1016/j.endonu.2016.07.008.
39. Mayatskaya T.A., Kharitonova L. A., Papysheva O. V., Zatevalov A. M. Formation of intestinal microbiocenosis in children born to mothers with gestational diabetes mellitus. Experimental and Clinical Gastroenterology. 2021;1(1):96-105. (In Russ.) doi: 10.31146/1682-8658-ecg-185-1-96-105.@@ Маяцкая Т. А., Харитонова Л. А., Папышева О. В., Затевалов А. М. Становление микробиоценоза кишечника у детей, рожденных от матерей с гестационным сахарным диабетом. Экспериментальная и клиническая гастроэнтерология. 2021;1(1):96-105. doi: 10.31146/1682-8658-ecg-185-1-96-105.
40. Soderborg T.K., Borengasser S. J., Barbour L. A., Friedman J. E. Microbial transmission from mothers with obesity or diabetes to infants: an innovative opportunity to interrupt a vicious cycle. Diabetologia. 2016 May;59(5):895-906. doi: 10.1007/s00125-016-3880-0.
41. Crusell M.K.W., Hansen T. H., Nielsen T. et al.Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes. Front Cell Infect Microbiol. 2020 Oct 23;10:536282. doi: 10.3389/fcimb.2020.536282.
42. Belyaeva I.A., Bombardirova E. P., Turti T. V., Mitish M. D., Potekhina T. V.Intestinal microbiota in premature infants - current state of the problem (literature review). Pediatric pharmacology. 2015;12(3):296-303. (in Russ.)@@ Беляева И. А., Бомбардирова Е. П., Турти Т. В., Митиш М. Д., Потехина Т. В. Кишечная микробиота у недоношенных детей - современное состояние проблемы (обзор литературы). Педиатрическая фармакология. 2015, Т. 12, № 3, С. 296-303.
43. Chervinets V. M., Chervinets Yu. V., Petrova O. A., Antonova L. K., Pogasyan S. V., Ganina E. B., Mironov A. Yu. Gastrointestinal microbiota of the newborns of the first month of life of the Tver region. Klinicheskaya laboratornaya diagnostika (Russian Clinical Laboratory Diagnostics). 2018; 63 (9): 579-583 (in Russ.) doi: 10.18821/0869-2084-2018-63-9-579-583.@@ Червинец В. М., Червинец Ю. В., Петрова О. А., Антонова Л. К., Погасян С. В., Ганина Е. Б., Миронов А. Ю. Микробиота желудочно-кишечного тракта новорожденных первого месяца жизни в тверской области. Клиническая лабораторная диагностика. 2018. Т. 63. № 9. С. 579-583. doi: 10.18821/0869-2084-2018-63-9-579-583.
44. Crusell M.K.W., Hansen T. H., Nielsen T. et al.Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes. Front Cell Infect Microbiol. 2020 Oct 23;10:536282. doi: 10.3389/fcimb.2020.536282.
45. Malygina O. G., Bazhukova T. A. Large bowel microbiocentosis in immature infants with very low and extremely low body weight in the first year of life. Journal of microbiology, epidemiology and immunobiology. 2018;5: 60-66. (in Russ.)@@ Малыгина О. Г., Бажукова Т. А. Становление микробиоценоза толстой кишки у недоношенных детей с очень низкой и экстремально низкой массой тела на первом году жизни. Журнал микробиологии, эпидемиологии и иммунобиологии. 2018. № 5. С. 60-66.
46. Korpela K., Blakstad E. W., Moltu S. J. et al.Intestinal microbiota development and gestational age in preterm neonates. Sci Rep. 2018 Feb 6;8(1):2453. doi: 10.1038/s41598-018-20827-x.
47. Makarova S.G., Broeva M. I. The influence of various factors on the early stages of the formation of intestinal microbiota. Pediatric pharmacology. 2016;13(3):270-282. (in Russ.)@@ Макарова С. Г., Броева М. И. Влияние различных факторов на ранние этапы формирования кишечной микробиоты. Педиатрическая фармакология. 2016. Т. 13. № 3. С. 270-282.
48. Younge N.E., Newgard C. B., Cotten C. M. et al. Disrupted Maturation of the Microbiota and Metabolome among Extremely Preterm Infants with Postnatal Growth Failure. Sci Rep. 2019 Jun 3;9(1):8167. doi: 10.1038/s41598-019-44547-y.
49. Zhou H., Sun L., Zhang S., Zhao X., Gang X., Wang G. Evaluating the Causal Role of Gut Microbiota in Type 1 Diabetes and Its Possible Pathogenic Mechanisms. Front Endocrinol (Lausanne). 2020 Mar 24;11:125. doi: 10.3389/fendo.2020.00125.
50. Ibragimova L.I., Kolpakova E. A., Dzagakhova A. V., Egshatyan L. V., Pokrovskaya E. V., Derevyanko O. S., Nikonova T. V. The role of the gut microbiota in the development of type 1 diabetes mellitus. Diabetes mellitus. 2021;24(1):62-69. (In Russ.) doi: 10.14341/DM10326.@@ Ибрагимова Л. И., Колпакова Е. А., Дзагахова А. В., Егшатян Л. В., Покровская Е. В., Деревянко О. С., Никонова Т. В. Роль микробиоты кишечника в развитии сахарного диабета 1 типа. Сахарный диабет. 2021. Т. 24. № 1. С. 62-69. doi: 10.14341/DM10326.
Review
For citations:
Chervinets V.M., Chervinets Yu.V., Ganzya D.V., Belyaev V.S., Zaitseva V.S. The effect of the intestinal microbiota on the development of diabetes mellitus. Experimental and Clinical Gastroenterology. 2023;(12):77-85. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-220-12-77-85
Views:
77
Email this article 